The Latest Oncology Journal Articles
The latest oncology journal articles in a single view, including medical oncology and radiation oncology. Articles are selected from the leading medical journals, including Journal of Clinical Oncology, Annals of Oncology and The Lancet Oncology.
You can navigate to the ‘Drugs’ section using the menu bar at the top of the page to find the latest research articles relating to specific oncology treatments.
For the latest articles relating to specific tumour / cancer types use the links in the list below:
- Breast cancer
- Gastrointestinal cancer
- Gynaecological cancer
- Haemato-oncology
- Lung cancer
- Skin cancer
- Urologic oncology
Latest Oncology Articles
- Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma.Effective treatment options are limited for patients with advanced (metastatic or unresectable) […]
- Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in BRCA1, BRCA2, or PALB2.Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi), is approved as maintenance […]
- Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer.Anaplastic thyroid cancer (ATC), an aggressive malignancy, is associated with a poor […]
- Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial.HER2 amplification has been identified in 2-3% of patients with colorectal cancer, […]
- Risk of colorectal cancer in first degree relatives of patients with colorectal polyps: nationwide case-control study in Sweden.To assess the risk of colorectal cancer (CRC) in first degree relatives […]
- Ixazomib, Daratumumab, and Low-Dose Dexamethasone in Frail Patients With Newly Diagnosed Multiple Myeloma: The Hovon 143 Study.Frail patients with newly diagnosed multiple myeloma have an inferior outcome, mainly […]
- Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509).Approved systemic therapies for advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) have shown limited […]
- Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma.Combination of antiprogrammed cell death protein-1 (PD-1) plus anti-cytotoxic T-cell lymphocyte-4 (anti-CTLA-4) […]
- Pertuzumab Plus High-Dose Trastuzumab in Patients With Progressive Brain Metastases and HER2-Positive Metastatic Breast Cancer: Primary Analysis of a Phase II Study.Effective therapies are needed for the treatment of patients with human epidermal […]
- Predictors of Cognitive Performance Among Infants Treated for Brain Tumors: Findings From a Multisite, Prospective, Longitudinal Trial.Infants treated for CNS malignancies experience a significantly poorer response to treatment […]
- Survival Benefit for Individuals With Constitutional Mismatch Repair Deficiency Undergoing Surveillance.Constitutional mismatch repair deficiency syndrome (CMMRD) is a lethal cancer predisposition syndrome […]
- Appropriate Systemic Therapy Dosing for Obese Adult Patients With Cancer: ASCO Guideline Update.To provide recommendations for appropriate dosing of systemic antineoplastic agents in obese […]
- A randomized phase III trial comparing trabectedin to best supportive care in patients with pre-treated soft tissue sarcoma: T-SAR, a French Sarcoma Group trial.The French Sarcoma Group assessed the efficacy, safety, and quality of life […]
- Adjuvant T-DM1 versus Trastuzumab in Patients with Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer: Subgroup Analyses from KATHERINE.In the KATHERINE study (NCT01772472), patients with residual invasive early breast cancer […]
- Practical considerations in screening for genetic alterations in cholangiocarcinoma.Cholangiocarcinoma (CCA) encompasses diverse epithelial tumors historically associated with poor outcomes due […]
- Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study.The efficacy and safety profiles of vaccines against SARS-CoV-2 in patients with […]
- Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation.BK virus-associated hemorrhagic cystitis (BKV-HC) is a common complication of allogenic hematopoietic […]
- TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors.Patients with metastatic urothelial carcinoma (mUC) who progress on platinum-based combination chemotherapy […]
- Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study.The first interim analysis of the phase III, randomized, placebo-controlled TITAN study […]
- Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin Lymphoma.To improve curability and limit long-term adverse effects for newly diagnosed early-stage […]
- Short Diagnosis-to-Treatment Interval Is Associated With Higher Circulating Tumor DNA Levels in Diffuse Large B-Cell Lymphoma.Patients with Diffuse Large B-cell Lymphoma (DLBCL) in need of immediate therapy […]
- National Marrow Donor Program-Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide.Hematopoietic cell transplantation (HCT) is curative for hematologic disorders, but outcomes are […]
- Management of Salivary Gland Malignancy: ASCO Guideline.To provide evidence-based recommendations for practicing physicians and other healthcare providers on […]
- Pemetrexed Plus Platinum With or Without Pembrolizumab in Patients With Previously Untreated Metastatic Nonsquamous NSCLC: Protocol-Specified Final Analysis From KEYNOTE-189.In the phase 3 KEYNOTE-189 study (NCT02578680), pembrolizumab plus pemetrexed and platinum-based […]
- Association of Germline BRCA Pathogenic Variants With Diminished Ovarian Reserve: A Meta-Analysis of Individual Patient-Level Data.To determine whether germline BRCA (gBRCA) pathogenic variants are associated with decreased […]
- Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39).To evaluate the addition of the humanized monoclonal antiprogrammed death ligand-1 (PD-L1) […]
- Cognitive and Adaptive Functioning in Youth With Retinoblastoma: A Longitudinal Investigation Through 10 Years of Age.To describe the trajectory of cognitive and adaptive functioning in pediatric patients […]
- Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial.Preoperative chemoradiotherapy according to the chemoradiotherapy for esophageal cancer followed by surgery […]
- Evidence-based approaches for the management of side-effects of adjuvant endocrine therapy in patients with breast cancer.The growing availability of more effective therapies has contributed to an increased […]
- Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.Patients with metastatic triple-negative breast cancer have a poor prognosis. Sacituzumab govitecan […]
- Neck Dissections Based on Sentinel Lymph Node Navigation Versus Elective Neck Dissections in Early Oral Cancers: A Randomized, Multicenter, and Noninferiority Trial.This study aimed to compare patients with early oral cavity squamous cell […]
- ROCK2 Inhibition With Belumosudil (KD025) for the Treatment of Chronic Graft-Versus-Host Disease.The rho-associated coiled-coil-containing protein kinase-2 (ROCK2) signaling pathway regulates the Th17/regulatory T […]
- Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50.We report the first 5-year follow-up of any first-line phase III immunotherapy […]
- Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020.Prior studies have evaluated the percentage of cancer patients with advanced or […]
- Induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by chemoradiotherapy in patients with stage III-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised, controlled, phase 3 trial.Cisplatin-based induction chemotherapy plus concurrent chemoradiotherapy in the treatment of patients with […]
- Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial.The European Organisation for Research and Treatment of Cancer (EORTC) 1325/KEYNOTE-054 trial […]
- Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial.The European Organisation for Research and Treatment of Cancer (EORTC) 1325-MG/KEYNOTE-054 trial […]
- Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial.Copanlisib, an intravenous pan-class I PI3K inhibitor, showed efficacy and safety as […]
- Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study.Few effective second-line treatments exist for women with recurrent or metastatic cervical […]
- Intraoperative irradiation for early breast cancer (ELIOT): long-term recurrence and survival outcomes from a single-centre, randomised, phase 3 equivalence trial.In the randomised, phase 3 equivalence trial on electron intraoperative radiotherapy (ELIOT), […]
- Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.The TAPUR Study is a phase II basket trial that aims to […]
- Surveillance for subsequent neoplasms of the CNS for childhood, adolescent, and young adult cancer survivors: a systematic review and recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group.Exposure to cranial radiotherapy is associated with an increased risk of subsequent […]
- Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2 trial.Treatment for poor prognosis metastatic castration-resistant prostate cancer (mCRPC) includes taxane chemotherapy […]
- Health-Related Quality of Life With Trastuzumab Monotherapy Versus Trastuzumab Plus Standard Chemotherapy as Adjuvant Therapy in Older Patients With HER2-Positive Breast Cancer.We report findings on quality of life (QoL) in the RESPECT trial, […]
- Impact of a Genomic Test on Treatment Decision in a Predominantly African American Population With Favorable-Risk Prostate Cancer: A Randomized Trial.The Genomic Prostate Score (GPS), performed on biopsy tissue, predicts adverse outcome […]
- Impact of Previously Unrecognized HLA Mismatches Using Ultrahigh Resolution Typing in Unrelated Donor Hematopoietic Cell Transplantation.Ultrahigh resolution (UHR) HLA matching is reported to result in better outcomes […]
- Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines.Colorectal cancer (CRC) is still a leading cause of cancer-related deaths in […]
- Excellent Outcome for Pediatric Patients With High-Risk Hodgkin Lymphoma Treated With Brentuximab Vedotin and Risk-Adapted Residual Node Radiation.Brentuximab vedotin, an effective anti-CD30 antibody-drug conjugate approved for use in adults […]
- Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium.The classification of the International Germ Cell Cancer Collaborative Group (IGCCCG) plays […]
- The Randomized AMBORA Trial: Impact of Pharmacological/Pharmaceutical Care on Medication Safety and Patient-Reported Outcomes During Treatment With New Oral Anticancer Agents.Oral anticancer drugs (eg, kinase inhibitors) play an important role in cancer […]
- Treatment of Pediatric Adrenocortical Carcinoma With Surgery, Retroperitoneal Lymph Node Dissection, and Chemotherapy: The Children’s Oncology Group ARAR0332 Protocol.Adrenocortical carcinoma (ACC) is a rare aggressive pediatric malignancy with distinct biology. […]
- Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer: The CALGB/SWOG 80702 (Alliance) Randomized Clinical Trial.Aspirin and cyclooxygenase 2 (COX-2) inhibitors have been associated with a reduced […]
- Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial.In the KEYNOTE-177 study, pembrolizumab monotherapy provided statistically significant and clinically meaningful […]
- 8th European Conference on Infections in Leukaemia: 2020 guidelines for the diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or post-haematopoietic cell transplantation.Paediatric patients with cancer and those undergoing allogeneic haematopoietic cell transplantation have […]
- 8th European Conference on Infections in Leukaemia: 2020 guidelines for the use of antibiotics in paediatric patients with cancer or post-haematopoietic cell transplantation.Paediatric patients with cancer and those undergoing haematopoietic cell transplantation are at […]
- Prospective Evaluation of Dietary and Lifestyle Pattern Indices with Risk of Colorectal Cancer in a Cohort of Younger Women.Although colorectal cancer (CRC) incidence in the US is declining overall, its […]
- Delayed immune-related adverse events with anti-PD1-based immunotherapy in melanoma.IrAEs typically occur within 4 months of starting anti-PD1-based therapy (anti-PD1 +/- […]
- Distinct genomic landscapes of gastroesophageal adenocarcinoma depending on PD-L1 expression identify mutations in RAS-MAPK pathway and TP53 as potential predictors of immunotherapy efficacy.The impact of molecular alterations on PD-L1 combined positive score (CPS) is […]
- Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial.Advanced biliary tract cancer has a poor prognosis. Cisplatin and gemcitabine is […]
- Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study.Alpelisib, a PI3Kα-selective inhibitor and degrader, plus fulvestrant showed efficacy in hormone […]